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Abstract 
Aim: Trefoil factor family 3 (TFF3) peptide is normally expressed by epithelial cells in breast ducts, 
but it is also associated with different pathological conditions, including breast cancer. It is considered 
a marker of poor prognosis and associated with increased resistance to chemotherapy. Data on the 
effect of chemotherapy on TFF3 peptide expression are scarce. The aim of this pilot study was to 
assess suitability of research on this topic for large-scale studies. 
Methods: Formalin-fixed, paraffin-embedded samples of core biopsies and of surgically removed 
tumors from patients with luminal B subtype of breast cancer were used for immunohistochemical 
analysis. Changes in TFF3 peptide and Ki-67 expression and microvessel density (MVD) values before 
and after chemotherapy were analyzed, as well as the association between TFF3 peptide expression 
and Ki-67 expression and MVD values. 
Results: Significant reduction in TFF3 and Ki 67 expression was observed after chemotherapy, while 
MVD values did not differ significantly before and after chemotherapy. The association of TFF3 
peptide expression and Ki-67 expression and TFF3 peptide expression and MVD values was not 
significant before or after chemotherapy. 
Conclusion: The data obtained in this pilot study suggest that a large-scale study is justified, and it 
other breast cancer subtypes should be included.  
(Bijelić N, Abramović M, Rajc J, Rođak E, Marušić Z, Tolušić Levak M, Pauzar B, Belovari T. Neoadjuvant 
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Introduction 
Early detection of breast cancer enables better 
treatment. Also, adequate methods for 
monitoring response to treatment help in 
planning further treatment. Modern breast 
cancer diagnostics include core biopsy with 
immunohistochemical characterization of tumor 
tissue. According to St. Galen consensus, breast 
cancer is classified into following surrogate 
subtypes:  luminal A, Her2-positive luminal B, 
Her2-negative luminal B, Her2-enriched and 
triple negative breast cancer. Such classification 
helps with prognosis and choice of therapy and 
is based on expression of estrogen receptor, 
progesterone receptor, Her2 and Ki 67 in the 
tumor [1]. Still, there is a need for further 
characterization of oncogenes and molecular 
markers connected to the onset, progression 
and relapse of breast cancer [2]. 
In modern breast cancer therapy, neoadjuvant 
chemotherapy is considered a standard 
approach in an increasing number of clinical 
settings (e. g. in patients with tumor subtypes 
that are highly sensitive to chemotherapy and in 
patients that have tumors > 2 cm and/or 
metastases in axillar lymph nodes), also allowing 
for cancer down-staging and helping with breast 
conservation [3,4]. It also alters expression of 
different markers in cancer cells, such as 
hormone receptors, Her2, claudin-1 and claudin-
3 [5,6]. 
Trefoil Factor Family (TFF) is a group of three 
small secretory peptides – TFF1, TFF2 and TFF3 
peptide, mostly secreted by epithelial cells of 
various mucosal sites. Their major role is 
mucosal protection, and they are known to 
affect cell migration, apoptosis, angiogenesis 
and immune response [7]. Of the three peptides, 
TFF3 peptide is the most widespread in the 
human organism, and is normally expressed by 
epithelial cells in breast ducts [8,9]. However, 
presence of TFF peptides is also associated with 
different pathological conditions, including 
breast cancer. TFF3 peptide is expressed in 
different subtypes of breast cancer, most 
predominantly in hormone receptor-positive 
subtypes and is considered a marker of poor 
prognosis because it promotes metastatic 
seeding and neoangiogenesis [10,11]. Our 
previous research showed that TFF3 peptide 
expression was the highest in luminal B subtype, 
moderately differentiated cancers (grade II) and 
in tumors with moderate expression of Ki 67, 
implying that TFF3 peptide might be considered 
a possible marker for determining tumor status, 
which might influence the choice of therapy [12]. 
Presence of TFF3 peptide in breast cancer cells 
is associated with increased resistance to 
chemotherapy, while cancers with complete 
response to chemotherapy have lower or no 
TFF3 peptide expression [13]. Despite the 
growing interest in TFF3 peptide research in the 
context of breast cancer diagnostics and 
therapy, there are no data on the effect of 
chemotherapy on TFF3 peptide expression in 
breast cancer tissue. Therefore, we launched a 
pilot study in order to assess the suitability of a 
large-scale study. 
Material and Methods  
Study design and material 
This was a cross-sectional pilot study performed 
on tissue samples archived at the Department of 
Pathology and Cytology, University Hospital 
Centre Zagreb. Tissue samples of luminal B 
subtype of breast cancer were used in the study. 
They were taken during routine diagnostic and 
therapy procedures from women whose 
treatment included neoadjuvant chemotherapy. 
There were 22 tumor samples overall; 10 were 
Her2-negative, and 12 were Her2-positive. Also, 
samples from 5 normal breast tissue controls 
were included for comparison of TFF3 peptide 
expression. For each tumor, a core biopsy 
sample (pre-chemotherapy) and a sample of 
surgically removed tumor (post-chemotherapy) 
were used. Chemotherapy protocols of each 
patient are available in the Supplemental table. 
Changes in TFF3 peptide and Ki-67 expression 
and in microvessel density (MVD) values before 
and after chemotherapy were analyzed, as well 
as the association between TFF3 peptide 
expression and Ki-67 expression and MVD 
values. 
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Immunohistochemical staining 
For each patient, archived immunostained slides 
(hormone receptor positivity, Ki-67 status and 
Her2 status) were revised in order to confirm the 
cancer subtype. Paraffin blocks of samples that 
met the criteria to be included in the study 
(luminal B subtype) were cut on a microtome 
(Leica, SM2000R, Leica Biosystems, Nussloch, 
Germany) into 3-5-µm-thick slides and mounted 
onto adhesive slides suitable for 
immunohistochemistry. Slides were stained for 
TFF3 peptide and CD34 endothelial marker, and 
Ki-67 staining scores (share of immunopositive 
nuclei) were obtained from the aforementioned 
archived slides. Antigen retrieval was performed 
using the Dako PT Link device (Dako, Agilent 
Technologies, Santa Clara, USA) with the 
EnVision FLEX Target Retrieval Solution, Low pH 
for TFF3 peptide and Ki-67 staining, and the 
Dako EnVision FLEX Target Retrieval Solution, 
High pH for CD34 staining. After that, the slides 
were stained in the Dako TechMate device using 
standard protocols as per the manufacturer’s 
instructions. Purified monoclonal mouse anti-
human primary antibody to TFF3 peptide was 
used at 1:1000 dilution (Sigma-Aldrich, St. Louis, 
USA), for Ki-67 monoclonal mouse, anti-human 
antibody was used at 1:75 dilution (Dako), and for 
CD34 monoclonal mouse, anti-human antibody 
was used at 1:50 dilution (Dako). For 
immunostaining visualization, the Dako EnVision 
FLEX kit was used. All slides were 
counterstained with hematoxylin, dehydrated 
and coverslipped using the Entellan covering 
medium (Merck, Darmstadt, Germany). For TFF3 
peptide staining, appendix tissue was used as 
positive control, while placenta tissue and the 
appendix tissue with primary antibody omitted 
were used as negative control. The appendix 
tissue was used as positive and negative control 
for CD34 (primary antibody omitted on negative 
controls). 
TFF3 peptide tissue expression level was 
assessed using a modified Quick score method 
that incorporates the share of immunopositive 
cells as well as staining intensity and reports the 
staining on a scale of 0 to 7 [12,14]. CD34 staining 
was used to obtain MVD (number of small blood 
vessels per surface unit under a 10 × objective) 
[15]. Digital photographs were taken using the 
Axiocam 305 color camera mounted on a Zeiss 
Axio imager A2 light microscope and ZEN 2.3 lite 
(blue edition) software (Carl Zeiss Microscopy 
GmbH, Jena, Germany). 
The investigations were carried out following the 
rules of institutional and national ethical 
standards and the rules of Helsinki Declaration 
of 1975, revised in 2013. The study has been 
approved by the ethical committees of the 
University Hospital Centre Zagreb (Class: 8.1-
18/256-2, No.: 02/21 A6) and the Faculty of 
Medicine Osijek (No. 2158-61-07-19-10). 
Statistical analysis 
Patient age was expressed using mean values 
and standard deviation, while all other data were 
expressed using the median and interquartile 
range. For comparison of dependent samples, 
the non-parametric Wilcoxon test was used, and 
the Kendall's Tau test was used for the analysis 
of the association of numerical variables. 
Coefficient of determination was obtained by 
linear regression after correlation testing. For 
comparison of independent samples, the Mann-
Whitney U test was used. 
Data on Ki 67 expression after chemotherapy 
were unavailable for two patients, and these 
were excluded from the analyses that included 
Ki 67 expression. The statistical analysis was 
done using the MedCalc software (18.11.6, 
MedCalc Software bvba, Ostend, Belgium) and a 
P-value less than 0.05 was considered 
statistically significant. 
Results 
The mean age of cancer patients was 53.1 years 
(st. dev. 13.2) at the time of diagnosis; the mean 
age of subjects with no cancer was 55.6 years  
(st. dev. 9.07). TFF3 peptide staining was 
detected both in breast cancer tissue and in 
normal breast tissue. 
The analysis of Quick score values for TFF3 
peptide expression in patients with luminal B 
subtype of breast cancer showed a significant 
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reduction in TFF3 peptide immunostaining after 
chemotherapy (Table 1, Figure 1). 
Table 1. TFF3 peptide expression, Ki 67 expression and MVD values in luminal B breast cancer 
subtype before and after chemotherapy 
 N Before 
chemotherapy 
After chemotherapy P-value* 
TFF3 Quick 
score 
22 6 (6 – 7) 5 (4 – 6) 0.005 
Ki-67 score (%) 20 31 (25 – 38.5) 11.5 (4.8 – 21) < 0.001 
MVD value 
(/mm2) 
22 79.9 (62.3 – 96.3) 71.3 (54.8 – 99.4) 0.59 
* Wilcoxon test 
Figure 1. Immunohistochemical staining of luminal B breast cancer tissue for TFF3 peptide 
 
a) Her2-positive cancer before chemotherapy (core biopsy), Quick score = 7; b) the same tumor after chemotherapy (surgical excision), Quick 
score = 3; c) Her2-negative cancer before chemotherapy (core biopsy), Quick score = 6; d) the same tumor after chemotherapy (surgical excision), 
Quick score = 4. Scale bar: 0.1 mm 
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Compared to normal breast epithelium, Quick 
score values did not differ significantly in breast 
cancer before chemotherapy, while after 
chemotherapy, the median Quick score value 
was lower and close to significant values (P = 
0.92 and 0.08, respectively; Mann-Whitney U 
test). Ki 67 expression in patients with breast 
cancer was significantly lower after 
chemotherapy (Table 1). Microvessels were 
identified by CD34 staining. On several slides, 
tissue fibroblasts caused some false positivity, 
which was excluded from MVD calculation. MVD 
values did not differ significantly before and 
after chemotherapy (Table 1). 
Supplemental Table 1. The table shows all cancer patients with their corresponding neoadjuvant 
therapy regimens and durations used in this study.  
Patient code Neoadjuvant therapy regimen (type and duration; notes) 
2 HER2- AC-T 6 months 
3 HER2- AC-T 6 months 
4 HER2- AC-T 6 months 
5 HER2- AC-T 6 months 
6 HER2- AC-T 5 months 
7 HER2- AC-T 7 months 
9 HER2- AC-T 6 months 
10 HER2- AC-T 6 months 
11 HER2- AC-D (3 x AC + 1 x D) 2 months; discontinued due to intolerance 
12 HER2- AC-D 2 months 
1 HER2+ ACdd 2 months + PHP 
2 HER2+ ACdd-THP* 6 months 
3 HER2+ AC-T 5 months**; trastuzumab 7 months 
4 HER2+ AC-T 6 months 
6 HER2+ AC-THP 6 months 
8 HER2+ AC-PHP 6 months 
9 HER2+ AC-PHP 5 months 
10 HER2+ AC-TH 7 months 
11 HER2+ AC-PHP 6 months 
12 HER2+ AC-T + 4 PH 7 months 
13 HER2+ AC-T + PH duration unknown 
14 HER2+ AC-THP 6 months 
* trastuzumab taken for only 3 months 
** regimen discontinued after the 4th paclitaxel dose 
Abbreviations: AC-D – doxorubicin, cyclophosphamide, docetaxel; ACdd –  dose-dense AC regimen; AC-T – doxorubicin, 
cyclophosphamide, paclitaxel; AC-PH – doxorubicin, cyclophosphamide, pertuzumab, trastuzumab; AC-PHP: 
doxorubicin, cyclophosphamide, paclitaxel, trastuzumab, pertuzumab; AC-TH – doxorubicin, cyclophosphamide, 
paclitaxel, trastuzumab; AC-THP – doxorubicin, cyclophosphamide, docetaxel, trastuzumab, pertuzumab 
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The association of TFF3 peptide expression and 
Ki 67 expression, as well as of TFF3 peptide 
expression and MVD values, was not significant 
before or after chemotherapy, although the P-
value for the association of TFF3 peptide 
expression and MVD values before 
chemotherapy was close to the significance 
level (Table 2).
Table 2. Association of TFF3 peptide with Ki-67 expression and MVD values in luminal B breast cancer 
subtype before and after chemotherapy 






Ki-67 0.04 -0.27 – 0.40 0.84 0.017 
MVD 0.28 -0.19 – 0.58 0.07 0.090 
After chemotherapy 
TFF3 
Ki-67 -0.25 -0.52 – 0.16 0.11 0.031 
MVD 0.25 -0.11 – 0.53 0.11 0.074 
* Kendall's Tau test 
 
Discussion 
This pilot study revealed a significant reduction 
in TFF3 peptide and Ki 67 expression after 
neoadjuvant chemotherapy, while no significant 
changes in MVD values were found. Until now, 
no data have been available on the effect of 
chemotherapy on TFF3 peptide expression in 
breast cancer cells or its association with Ki-67 
and MVD before and after chemotherapy. Since 
it is known that overexpression of TFF3 peptide 
affects proliferation of breast cancer cells, 
stimulates angiogenesis and contributes to 
chemotherapy resistance, information about the 
effect of chemotherapy on TFF3 peptide 
expression should be helpful in understanding 
its role in breast cancer [11,13]. 
Although expression of TFF3 peptide increases 
the chances of local invasion and metastatic 
seeding, its role in breast cancer is still not fully 
understood [10]. Some researchers argue that it 
should not be considered an oncogene, but a 
normal breast protein “abused” by cancer cells, 
and similar conclusions could be drawn from 
other diseases involving TFF3 peptide 
expression [9,16]. Due to its effect on disease 
progression and chemotherapy results, TFF3 
peptide is considered a potential therapeutic 
target in certain types of breast cancer, and 
current research looks promising [13,17,18]. 
Nevertheless, since TFF3 peptide has important 
physiological roles in the human organism, a 
careful risk/benefit assessment is needed. For 
example, TFF3 peptide is important for 
maintenance of intestinal mucosa, which is often 
affected by chemotherapy, hence targeting 
TFF3 peptide might worsen certain 
chemotherapy side-effects [19]. 
Newly-formed small blood vessels can be an 
early predictor of metastatic potential, and CD34 
is one of the most important endothelial markers 
used for small vessel detection [20]. MVD values 
did not change significantly in this research, and 
the correlation between MVD and TFF3 Quick 
score was weak. Hence, although TFF3 peptide 
stimulates angiogenesis, it seems that a 
reduction in TFF3 expression after 
chemotherapy did not affect tumor vascularity. 
A reduction in Ki 67 expression was expected, 
although it was interesting to see that there was 
no significant association between TFF3 peptide 
and Ki 67 expression before or after 
chemotherapy, probably due to different 
mechanisms regulating their expression.  
Limitations to this pilot study were the analysis 
of only one subtype of breast cancer and 
sample size. Nevertheless, based on the data 
obtained, we believe a large-scale study 
including other breast cancer subtypes is 
justified.  Since TFF3 is a secretory protein found 
in different body liquids, there is also a possibility 
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of a quantitative evaluation of TFF3 levels (e.g. in 
serum) by diagnostic methods. Such sampling is 
less invasive than a core or surgical biopsy and 
could be used as a screening method in certain 
conditions, which should be further investigated 
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